UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 2)
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 7, 2017
OncBioMune Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| Nevada | | 000-52218 | | 20-2590810 |
(State or other jurisdiction
of incorporation) | | (Commission
File No.) | | (IRS Employer
Identification No.) |
11441 Industriplex Blvd, Suite 190. Baton Rouge, LA | | 70809 |
| (Address of principal executive offices) | | (Zip Code) |
(225) 227-2384
Registrant’s telephone number, including area code
Not applicable.
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
EXPLANATORY NOTE
On March 13, 2017, OncBioMune Pharmaceuticals, Inc. filed a Current Report on Form 8-K (as amended by Amendment No. 1 filed on March 31, 2017, the “Original Form 8-K”) to report, among other things, the completion of the acquisition of all of the issued and outstandingcapital stock of Vitel Laboratorios, S.A. de C.V., a Mexican variable stock corporation (“Vitel”)fromits shareholders Manuel Cosme Odabachian and Carlos Fernando Alaman Volnie. This Amendment No. 2 to the Original Form 8-K amends and supplements Item 9.01 of the Original Form 8-K to include the financial information described in Item 9.01 below which was not previously filed with the Original Form 8-K. Except as stated in the Explanatory Note, no other information contained in the Original Form 8-K is changed.
| Item 9.01. | Financial Statements and Exhibits. |
| | (a) | Financial Statements of Business Acquired |
The audited financial statements of Vitel contemplated by this Item are filed as Exhibit 99.1 to this Amendment No. 2 to Current Report on Form 8-K and incorporated herein by reference.
| | (b) | Pro Forma Financial Information |
The pro forma financial information contemplated by this Item is filed as Exhibit 99.2 to this Amendment No. 2 to Current Report on Form 8-K and incorporated herein by reference.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | ONCBIOMUNE PHARMACEUTICALS, INC. |
| | | |
| Dated: July 2, 2018 | By: | /s/ Jonathan F. Head |
| | | Jonathan F. Head, |
| | | Chief Executive Officer |
